Argent BioPharma Limited (LON:MXC – Get Free Report) shot up 4.8% during trading on Friday . The stock traded as high as GBX 22 ($0.28) and last traded at GBX 22 ($0.28). 264 shares were traded during mid-day trading, a decline of 99% from the average session volume of 26,353 shares. The stock had previously closed at GBX 21 ($0.27).
Argent BioPharma Stock Performance
The stock has a market cap of £9.65 million, a price-to-earnings ratio of -13.25 and a beta of 1.03. The business has a 50-day simple moving average of GBX 22 and a two-hundred day simple moving average of GBX 21.75.
About Argent BioPharma
MGC Pharmaceuticals Limited provides phytomedicines worldwide. The company produces and supplies medicinal cannabis products; and non-cannabis phytomedicines. Its principal product candidates include CimetrA, which is in phase III clinical trial for the symptomatic treatment of early COVID-19; CannEpil, a phase IIb cannabis-based therapy for drug-resistant Epilepsy; and CogniCann that is in phase II clinical trial for the symptomatic relief of Dementia.
Featured Stories
- Five stocks we like better than Argent BioPharma
- 3 Tickers Leading a Meme Stock Revival
- FinWise Bancorp’s CEO Talks Strategy Behind Fintech Success
- Are These Liquid Natural Gas Stocks Ready For An Upside Bounce?
- Broadcom: Turning the Mag 7 Into 8 Trillion-Dollar Tech Giants
- How Investors Can Identify and Successfully Trade Gap-Down Stocks
- SoundHound AI: Can Its Meteoric Rise Sustain Into 2025?
Receive News & Ratings for Argent BioPharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Argent BioPharma and related companies with MarketBeat.com's FREE daily email newsletter.
